Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
CONTEXT: Heterozygous familial hypercholesterolemia (HeFH) is a common disorder associated with early coronary artery disease, especially in men. The age at which drug therapy should be started is still controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). OBJECTIVE: To assess the lipid-lowering efficacy, biochemical safety, and effect on growth and sexual development of lovastatin in adolescent boys with HeFH. DESIGN: One-year, double-blind, placebo-controlled, balanced, 2-period, 2-arm randomized trial. In the first period (24 weeks), lovastatin was increased at 8 and 16 weeks and the dosage remained stable during the second period (24 weeks). The study was conducted between 1990 and 1994. SETTING: Fourteen pediatric outpatient clinics in the United States and Finland. PATIENTS: Boys aged 10 to 17 years with HeFH. Of 132 randomized subjects (67 intervention, 65 placebo), 122 (63 intervention, 59 placebo) and 110 (61 intervention, 49 placebo) completed the first and second periods, respectively. INTERVENTION: Lovastatin, starting at 10 mg/d, with a forced titration at 8 and 16 weeks to 20 and 40 mg/d, respectively, or placebo. MAIN OUTCOME MEASURES: The primary efficacy outcome measure was low-density lipoprotein cholesterol (LDL-C). Primary safety measures were growth and sexual development. RESULTS: Compared with placebo, LDL-C levels of patients receiving lovastatin decreased significantly (P<.001) by 17%, 24%, and 27% receiving dosages of 10, 20, and 40 mg/d, respectively, and remained 25 % lower than baseline at 48 weeks. Growth and sexual maturation assessed by Tanner staging and testicular volume were not significantly different between the lovastatin and placebo groups at 24 weeks (P = .85) and 48 weeks (P = .33); neither were serum hormone levels or biochemical parameters of nutrition. However, the study was underpowered to detect significant differences in safety parameters. Serum vitamin E levels were reduced with lovastatin treatment consistent with reductions in LDL-C, the major carrier of vitamin E in the circulation. CONCLUSIONS: This study in adolescent boys with HeFH confirmed the LDL-C-reducing effectiveness of lovastatin. Comprehensive clinical and biochemical data on growth, hormonal, and nutritional status indicated no significant differences between lovastatin and placebo over 48 weeks, although further study is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citationVariations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Nonparametric Statistical Methods.
Moore, D. S., Hollander, M., & Wolfe, D. A. (1974) · Journal of the American Statistical Association · doi:10.2307/2285701 · Cited by 2,857
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents
(1991) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(21)07128-5 · Cited by 912
A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Mehta, C. R., & Patel, N. R. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477989 · Cited by 898
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 623
Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia
STONE, N. J., LEVY, R. I., FREDRICKSON, D. S., & VERTER, J. (1974) · Circulation · doi:10.1161/01.cir.49.3.476 · Cited by 475
Myers, G. L., Cooper, G. R., Winn, C. L., & Smith, S. J. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30645-0 · Cited by 404
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
SHEPHERD, J., COBBE, S. M., FORD, I., ISLES, C. G., LORIMER, A. R., MACFARLANE, P. W., MCKILLOP, J. H., & PACKARD, C. J. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.029 · Cited by 245
HAVEL, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., LEES, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-609 · Cited by 213
Self-citationShort-Term Efficacy and Safety of Pravastatin in 72 Children with Familial Hypercholesterolemia
Knipscheer, H. C., Boelen, C. C. A., Kastelein, J. J. P., Van Diermen, D. E., Groenemeijer, B. E., Van Den Ende, A., Büller, H. R., & Bakker, H. D. (1996) · Pediatric Research · doi:10.1203/00006450-199605000-00021 · Cited by 166
ANGINA PECTORIS IN HEREDITARY XANTHOMATOSIS
MÜLLER, C. (1939) · Archives of Internal Medicine · doi:10.1001/archinte.1939.00190040016002 · Cited by 162
Tonstad, S., Knudtzon, J., Sivertsen, M., Refsum, H., & Ose, L. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70188-9 · Cited by 161
Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin
Lambert, M., Lupien, P.-J., Gagné, C., Lévy, E., Blaichman, S., Langlois, S., Hayden, M., Rose, V., Clarke, J. T. R., Wolfe, B. M. J., et al. (1996) · Pediatrics · doi:10.1542/peds.97.5.619 · Cited by 157
Harrison, R., & Ashton, C. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04268.x · Cited by 113
Niacin Treatment of Hypercholesterolemia in Children
Colletti, R. B., Roff, N. K., Neufeld, E. J., Baker, A. L., Newburger, J. W., & McAuliffe, T. L. (1993) · Pediatrics · doi:10.1542/peds.92.1.78 · Cited by 106
Double blind trial of bezafibrate in familial hypercholesterolaemia.
Wheeler, K., West, R., Lloyd, J. K., & Barley, J. (1985) · Archives of Disease in Childhood · doi:10.1136/adc.60.1.34 · Cited by 87
Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine.
West, R., Lloyd, J., & Leonard, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92044-9 · Cited by 78
Kostis, J. B., Rosen, R. C., & Wilson, A. C. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb01971.x · Cited by 73
Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients
Stein, E. A., Davidson, M. H., Dobs, A. S., Schrott, H. G., Dujovne, C. A., Bays, H. E., Weiss, S. R., Melino, M. R., Stepanavage, M. E., & Mitchel, Y. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00421-4 · Cited by 72
Self-citationKaplan, L., Miller, J. A. O., & Stein, E. A. (1987) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860010202 · Cited by 71
Self-citationDucobu, J., Brasseur, D. J., Chaudron, J.-M., Deslypere, J.-P., Harvengt, C., Muls, E., & Thomson, M. (1992) · The Lancet · doi:10.1016/0140-6736(92)92092-t · Cited by 67
Stein, E., Shapero, J., McNerney, C. A., Glueck, C. J., Tracy, T., & Gartside, P. S. (1982) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/35.6.1375 · Cited by 59
Self-citationEffects of treatment with lovastatin and pravastatin on daytime cognitive performance
Gengo, F., Cwudzinski, D., Kinkel, P., Block, G., Stauffer, L., & Lines, C. (1995) · Clinical Cardiology · doi:10.1002/clc.4960180406 · Cited by 53
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate
Steinmetz, J., Morin, C. L., Panek, E., et al. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90267-9 · Cited by 48
Schrott, H. G., Stein, E. A., Dujovne, C. A., Davidson, M., Goris, G. B., Oliphant, T. H., Phillips, J. C., & Shawaryn, G. G. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80523-2 · Cited by 47
Self-citationCutler, N., Sramek, J., Veroff, A., Block, G., Stauffer, L., & Lines, C. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04458.x · Cited by 43
Donahue, R. P., Orchard, T. J., Stein, E. A., & Kuller, L. H. (1986) · Journal of Chronic Diseases · doi:10.1016/0021-9681(86)90084-6 · Cited by 24
Self-citationSleep Disturbance and HMG CoA Reductase Inhibitors
Black, D. M. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450090041020 · Cited by 24
Groot, P. H. E., Dijkhuis‐Stoffelsma, R., Grose, W. F. A., Ambagtsheer, J. J., & Fernandes, J. (1983) · Acta Paediatrica · doi:10.1111/j.1651-2227.1983.tb09668.x · Cited by 17
Cited by
Care of Children and Adolescents With Type 1 Diabetes
Silverstein, J., Klingensmith, G., Copeland, K., Plotnick, L., Kaufman, F., Laffel, L., Deeb, L., Grey, M., Anderson, B., Holzmeister, L. A., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.186 · Cited by 1,312
“Short-term trials of HMG-CoA reductase inhibitors in youth have confirmed their safety and efficacy (168,169) in youth with familial hypercholesterolemia.”
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Self-citationThe safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Williams, C. L., Hayman, L. L., Daniels, S. R., Robinson, T. N., Steinberger, J., Paridon, S., & Bazzarre, T. (2002) · Circulation · doi:10.1161/01.cir.0000019555.61092.9e · Cited by 774
Self-citation
Metadata
- Authors
- Stein, E. A., Illingworth, D. R., Kwiterovich, Jr., Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P., Davidson, M., Graham, K., Arensman, F., Knopp, R. H., DuJovne, C., Williams, C. L., Isaacsohn, J. L., Jacobsen, C. A., Laskarzewski, P. M., Ames, S., & Gormley, G. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-01-13
- Volume
- 281
- Issue
- 2
- Pages
- 137
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2125639599
- Cited by
- 270
- References
- 41
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.